Microchip's partner submits Chidamide's listing application in Japan and is accepted

On April 28, Microchip released an announcement stating that its partner Huya Bio-International Co.
, Ltd.
(a U.
S.
company, “Huya” for short) has recently requested the Japan Pharmaceuticals and Medical Devices Agency (PMDA) on Chidamide (overseas).
Number: HBI-8000) Single-drug treatment of relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) has submitted a new drug marketing application (NDA) and was accepted
.

Chidamide is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and the world's first oral administration approved for the treatment of peripheral T-cell lymphoma and combined with endocrine drugs for the treatment of estrogen receptor-positive breast cancer patients The drug, targeting class I histone deacetylase (HDAC), induces cell cycle arrest, inhibits the expression of a variety of oncogenes, regulates the acetylation of PD-L1, and enhances the activity of immune checkpoint inhibitors.
Epigenetic regulator drugs
.

Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous abnormal malignant proliferation of lymphocytes.
It belongs to non-Hodgkin's lymphoma, including mature T-cell and NK-cell tumors derived from the thymus
.